ID Source | ID |
---|---|
PubMed CID | 189150 |
CHEMBL ID | 1235115 |
CHEBI ID | 49093 |
SCHEMBL ID | 328998 |
MeSH ID | M0087276 |
Synonym |
---|
CHEMBL1235115 |
keto-d-tagatose 1,6-bisphosphate |
CHEBI:49093 , |
1,6-di-o-phosphono-d-tagatose |
keto-d-tagatose 1,6-bis(dihydrogen phosphate) |
DB02512 |
p6t , |
55529-38-9 |
tagatose 1,6-diphosphate |
d-tagatose 1,6-diphosphate |
d-tagatose 1,6-bis(dihydrogen phosphate) |
SCHEMBL328998 |
DTXSID30204099 |
hexosediphosphat |
Q27093497 |
PD007907 |
Class | Description |
---|---|
D-tagatose 1,6-bisphosphate | A ketohexose bisphosphate that is D-tagatose carrying phosphate groups at positions 1 and 6. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1419069 | Inhibition of rabbit muscle fructose-bisphosphate aldolase using FBP as substrate and NADH by spectrophotometry based coupled enzyme assay | 2018 | Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23 | Bisphosphonate Inhibitors of Mammalian Glycolytic Aldolase. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (30.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (50.00) | 29.6817 |
2010's | 2 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |